Targeted Immunotherapy in Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (20 May 2024) | Viewed by 1470

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microbiology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35294, USA
Interests: immunotherapy; cancer; HIV; humanized mouse model; breast cancer; ovarian cancer; lung cancer; lymphoma; metastasis; brain tumor

Special Issue Information

Dear Colleagues,

Cancer immunotherapy is a revolutionary approach in the field of cancer treatment that harnesses the power of the immune system to fight cancer cells. It represents a significant paradigm shift from traditional cancer treatments such as surgery, chemotherapy, and radiation therapy. While cancer immunotherapy has shown remarkable success in treating certain types of cancer, it is important to acknowledge the challenges and limitations that present specifically and effectively, particularly in targeting cancer cells.

Targeted cancer immunotherapy is a promising approach to overcome the limitations of current standard cancer treatment. By delivering immunotherapeutics specifically to target locations, undesired immune responses can be minimized, and the exhaustion of anti-cancer effector cells can be prevented. This Special Issue aims to provide a comprehensive overview of the latest advancements and emerging trends in targeted cancer immunotherapy. We welcome original research articles, reviews, and perspective articles on this theme. Topics may include, but are not limited to:

  • Novel technology to deliver immunotherapeutics to target locations.
  • On–off switch for CAR-T cell therapy.
  • Providing cancer-targeting moiety to immunotherapeutics.
  • Immunotherapy-related toxicities and management.
  • Translational research in cancer immunotherapy using an advanced animal model.

Dr. Masakazu Kamata
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • targeted therapy
  • metastatic cancer
  • animal model
  • nanomedicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1783 KiB  
Article
Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
by Keren Rouvinov, Gal Mazor, Ella Kozlener, Amichay Meirovitz, Noa Shani Shrem, Omar Abu Saleh, Sondos Shalata, Alexander Yakobson and Walid Shalata
J. Pers. Med. 2023, 13(11), 1623; https://doi.org/10.3390/jpm13111623 - 20 Nov 2023
Cited by 1 | Viewed by 1171
Abstract
In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI’s in penile squamous cell carcinoma (pSCC) we performed a retrospective observational study. We reviewed electronic medical [...] Read more.
In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI’s in penile squamous cell carcinoma (pSCC) we performed a retrospective observational study. We reviewed electronic medical records of patients with penile squamous cell carcinoma (SCC), diagnosed between January 2020 and February 2023. Nine patients were screened, of whom three were ineligible for chemotherapy and received immunotherapy, cemiplimab, in a first-line setting. Each of the three immunotherapy-treated patients achieved almost a complete response (CR) after only a few cycles of therapy. The first patient had cerebral arteritis during treatment and received a high-dose steroid treatment with resolution of the symptoms of arteritis. After tapering down the steroids dose, the patient continued cemiplimab without further toxicity. The other two patients did not have any toxic side effects of the treatment. To the best of our knowledge, this is the first real world report of near CR with cemiplimab as a first-line treatment in penile SCC. Full article
(This article belongs to the Special Issue Targeted Immunotherapy in Cancer)
Show Figures

Figure 1

Back to TopTop